Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM) -- Ignore unavailable to you. Want to Upgrade?

To: Starowl who wrote (506)	6/24/2004 12:48:52 PM
From: Dick Martin	Read Replies (1) \| Respond to of 655

We made it through the AGM and Fda approval for the cardiac tests but the shares have dropped on low volume,in particular share price seems to have been effected by the most recent financing. RBM is going to need the cash to enter the diverse number of marketing opportunities that are coming forward. I think important news is still waiting,annoucement of marketing arangments and initial sales of RAMP. When this comes there will more investor interest in these shares which I do not expect to go below .80. Dick > Biomedical Corp. NEWS > RELEASE > > 8081 Lougheed Highway > Burnaby, British Columbia > Canada V5A 1W9 > TSX Venture Exchange: RBM > <<...OLE_Obj...>> > Response Biomedical Begins Phase II Development > of a Biotech Trait Detection Test for Grain > > Vancouver, British Columbia, June 24, 2004 - Response Biomedical Corp. > (TSX-V: RBM) today announced the Company has initiated Phase II of an R&D > project toward the development of a rapid quantitative RAMP* Biotech Test. > This project, funded by a leading international biotechnology company, is > designed to identify biotech traits in harvested grain. > > "Having successfully completed a preliminary feasibility program, we are > expediting the development of the first RAMP Test for review beginning > this summer," states Bill Radvak, President and CEO. "As the Company's > lead entree into the agricultural food and grain testing market, recent > international regulatory and policy reform present an exciting and timely > opportunity for RAMP in rapid on-site testing for biotechnology traits, > initially in soy." > > "Conventional testing of biotechnology crops includes both lab-based > equipment and early generation qualitative immunoassay tests. Since RAMP > is an entirely new class of diagnostic system that provides lab-quality > information in a rapid portable platform, we are confident RAMP can become > the industry standard for quantifying seeds and crops improved by > biotechnology," adds Radvak. "This test also compliments our existing RAMP > product lines and other product concepts currently under development." > > > About Response Biomedical: > Response Biomedical develops, manufactures and markets rapid on-site > diagnostic tests for use with its RAMP System for clinical and > environmental applications, providing reliable information in minutes, > anywhere, every time. RAMP represents a new paradigm in diagnostic > testing, with the potential to be adapted to more than 250 medical and > non-medical tests currently performed in laboratories. The RAMP System > consists of a portable fluorescent Reader and single-use, disposable Test > Cartridges. RAMP tests are commercially available for the early detection > of heart attack, environmental detection of West Nile virus, and > biodefense applications including the rapid on-site detection of anthrax, > smallpox, ricin and botulinum toxin. The Company has achieved CE Mark and > its Quality Management System is registered to ISO 13485: 1996. > > Response Biomedical is a publicly traded company, listed on the TSX > Venture Exchange under the trading symbol "RBM". For further information, > please visit the Company's website at www.responsebio.com . > > The TSX Venture Exchange has not reviewed and does not accept > responsibility for the adequacy of the content of the information > contained herein. The statements made in this press release may contain > certain forward-looking statements that involve a number of risks and > uncertainties. Actual events or results may differ from the Company's > expectations. > > Contact: > Don Bradley > Director, Corporate Communications > Response Biomedical Corp. > Tel (604) 681- 4101 ext. 202 > Email: dbradley@responsebio.com > Jonathan Fassberg > President > The Trout Group LLC > Tel: (212) 477-9007 ext. 16 > Email: jfassberg@troutgroup.com Delete & Prev \| Delete & Next Move to: